I believe we have a bottom. Money woes not so woeful anymore. Stock held fairly steady after the drop post-dilution last time until early May when they announced trial enrollment delay, then we tanked to 1.57. We now have a solid plan to fund the company for many months, which will be a good base for partnership negotiations after trial results come in next Spring. I believe the company is quite excited by the value of these trials, and there will be significant interest, especially if they show some superiority in Type 1. Type 2 trial is a slam dunk and should allow many more physicians to be comfortable prescribing Afrezza earlier in the course of the disease. wells